

## **Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference**

**Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on Thursday, April 3, 2025.**

### **One-on-one and group meetings**

Thursday, April 3, 2025.

### **For further information, please contact**

Damian Marron, Interim CEO

Telephone: +46 (0)46-275 62 60

E-mail: [damian.marron@cantargia.com](mailto:damian.marron@cantargia.com)

### **About Cantargia**

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at [www.cantargia.com](http://www.cantargia.com).

### **Attachments**

**[Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference](#)**